Portal de recerca
BETAEVAL - EL NUEVO AUTOINYECTOR BETACONNECT™: ADHERENCIA AL TRATAMIENTO Y EVALUACIÓN DE PACIENTES CON ESCLEROSIS MÚLTIPLE (EM) TRATADOS CON BETAFERON®.
Dades bàsiques
- Protocol:
- BAY-INT-2014-01
- EURDRACT:
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2015
- Any de finalització:
- 2016
Objectius del projecte
Observaciones: Estado Comité: ACTIVO
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review.
Mansilla-Polo M, Gimeno E, Morgado-Carrasco D
Article. 10.1016/j.ad.2024.01.009. 2024
A guide to treating gait impairment with prolonged-release fampridine (Fampyra (R)) in patients with multiple sclerosis
Ramio-Torrenta, L; (...); Saiz, A
Review. 10.1016/j.nrl.7015.11.013. 2018
An algorithm to predict intrathecal synthesis of IgG with high efficiency
Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura
Meeting Abstract. 2023
An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.
Bracher A; (...); Dornmair K
Article. 10.1002/acn3.50974. 2020
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease
Höftberger R; (...); Saiz A
Article. 10.1177/1352458514555785. 2015
Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
Álvarez-Sánchez L; (...); Cháfer-Pericás C
Article. 10.3390/ijms24021226. 2023
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD; (...); Comabella M
Article. 10.1212/NXI.0000000000200270. 2024
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal, Enric; (...); Villar LM
Article. 10.1001/jamaneurol.2023.0010. 2023
Atypical periodic alternating nystagmus responding to high-dose intravenous immunoglobulins: a case report
Argente-Escrig, H; (...); Casanova Estruch B
Article. 10.1186/s12974-017-0846-1. 2017
Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Burman, J; (...); Farge, D
Article. 10.1038/bmt.2017.40. 2017
Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.
Boix Lago, A.; (...); Casanova Estruch, B.
Meeting Abstract. 2023
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients
Mathur, D; (...); Lopez-Rodas, G
Article. 10.3389/fncel.2017.00209. 2017
Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies
Navarro Canto, L.; (...); Casanova Estruch, B.
Meeting Abstract. 2019
Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype
Canto, LN; (...); Estruch, BC
Article. 10.3389/fneur.2019.01157. 2019
Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.
Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura
Article. 10.1002/brb3.2044. 2021
Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects
Mathur D; (...); Burgal-Marti M
Article. 10.3389/fncel.2015.00375. 2015
Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
Quintanilla-Bordás C; (...); Casanova B
Article. 10.3389/fneur.2022.897275. 2022
Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis
Gil-Perotin, S.; (...); Casanova, B.
Meeting Abstract. 2021
Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study
Lacruz-Ballester, L.; (...); Casanova-Estruch, B.
Meeting Abstract. 2021
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study
Oreja-Guevara, Celia; (...); Rio, Jordi
Article. 10.1016/j.msard.2024.105787. 2024
Clinical evaluation of rituximab treatment for neuromyelitis optica
Fernández-Megía MJ; (...); Poveda-Andrés JL
Article. 10.1016/j.nrl.2014.09.001. 2015
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2024.1477335. 2024
Clinical, demographic and laboratory data associated with PML risk in patients treated with natalizumab
Toboso, I; (...); Villar, LM
Meeting Abstract. 2017
Cognitive impairment in multiple sclerosis: diagnosis and monitoring.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-021-05165-7. 2021
Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Lopez-Soley, Elisabet; (...); Solana, Elisabeth
Meeting Abstract. 2022
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.
Lopez-Soley E; (...); Solana E
Article. 10.3390/jpm12050743. 2022
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; (...); Casanova B
Article. 10.3389/fneur.2019.01008. 2019
Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients
Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco
Article. 10.1155/2024/1950913. 2024
Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
Medina-Polo J; (...); López-Fando L
Article. 10.1002/nau.24276. 2020
Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Consensus on early detection of disease progression in patients with multiple sclerosis
Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia
Article. 10.3389/fneur.2022.931014. 2022
Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.
Brändle SM; (...); Dornmair K
Article. 10.1073/pnas.1916337118. 2021
CSF chitinase 3-like-1 association with disability of primary progressive MS
Perez-Miralles, F; (...); Casanova, B
Article. 10.1212/NXI.0000000000000815. 2020
Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients
Miralles, FP; (...); Casanova, B
Meeting Abstract. 2019
Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis
Izquierdo Ayuso, G.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2018
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.
Balzano T; (...); Felipo V
Article. 10.1016/j.jhep.2019.01.008. 2020
Deciphering Multiple Sclerosis Progression.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos
Review. 10.3389/fneur.2021.608491. 2021
Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade
Ribes García S; (...); Casanova Estruch B
Article. 10.1159/000446580. 2016
Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.
Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura
Article. 10.1159/000519772. 2022
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-018-3442-y. 2018
DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva, Luis; (...); Moral, Ester
Article. 10.1016/j.msard.2022.103805. 2022
Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects
Mathur, D; (...); Burgal-Marti, M
Article. 10.3390/brainsci8010001. 2018
Does benign multiple sclerosis exist?
Verdini Martinez, Laura; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study
Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1007/s13760-020-01516-x. 2020
Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo
Article. 10.3390/ijms241814151. 2023
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana, J E; (...); Calles Hernandez, C
Article. 10.1016/j.nrleng.2021.06.006. 2023
Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study
Meca-Lallana, J. E.; (...); Hernandez, C. Calles
Article. 10.1016/j.nrl.2021.06.007. 2024
Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases
Megias-Vericat, JE; (...); Poveda, JL
Review. 10.1007/s10072-017-2833-9. 2017
Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study
Oreja-Guevara, C.; (...); Meca-Lallana, J. E.
Meeting Abstract. 2021
Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Eculizumab for a catastrophic relapse in NMOSD: case report.
Gorriz, David; (...); Casanova, Bonaventura
Article. 10.1007/s10072-023-06971-x. 2023
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE; (...); Llarena C
Article. 10.1007/s40120-023-00557-7. 2023
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcala, Carmen; (...); Casanova, Bonaventura
Article. 10.1007/s00415-022-10989-0. 2022
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.
Villoslada P; (...); NeuroAdvan study
Article. 10.1212/NXI.0000000000000147. 2015
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-018-8899-3. 2018
Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis
Gil-Perotin, S; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
Quintanilla-Bordás C; (...); Pérez-Miralles FC
Case Reports. 10.3389/fimmu.2024.1465678. 2024
Escalation vs. Early Intense Therapy in Multiple Sclerosis.
Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco
Article. 10.3390/jpm12010119. 2022
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Evaluation of neuronal and glial serum biomarkers in patients with MOGAD: the MULTIMOGAD study
Villacieros-Alvarez, Javier; (...); Marignier, Romain
Meeting Abstract. 2024
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM; (...); Sancho JM
Article. 10.3324/haematol.2023.283342. 2024
Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
Ladrón Abia P; (...); Bastida Paz G
Letter. 10.1016/j.gastrohep.2020.07.020. 2021
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Castillo-Villalba, Jessica; (...); Casanova, Bonaventura
Article. 10.3389/fimmu.2022.827738. 2022
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
Zubizarreta, I; (...); Villoslada, P
Article. 10.1073/pnas.1820039116. 2019
Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension
Zubizarreta, I; (...); Villoslada, P
Meeting Abstract. 2019
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis
Edo Solsona MD; (...); Poveda Andrés JL
Article. 10.2147/PPA.S127508. 2017
IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS
Edo-Solsona, M.; (...); Poveda-Andres, J.
Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study
Meca-Lallana, Jose E.; (...); Maurino, Jorge
Article. 10.1007/s40120-022-00356-6. 2022
Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective
Meca-Lallana, Jose; (...); Maurino, Jorge
Meeting Abstract. 10.1016/j.jns.2021.118844. 2021
Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study
Meca Lallana, Jose; (...); Forner, Mireia
Meeting Abstract. 10.1212/WNL.0000000000202381. 2023
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.
Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo
Article. 10.1186/s41687-024-00822-9. 2024
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2023.104997. 2023
In Situ RT-PCR Optimized For Electron Microscopy Allows Description Of Subcellular Morphology Of Target mRNA-Expressing Cells In the Brain
LAURA CUBAS NÚÑEZ; (...); Gil-Perotin S
Article. 2017
In situ RT-PCR Optimized for Electron Microscopy Allows Description of Subcellular Morphology of Target mRNA-Expressing Cells in the Brain
Cubas-Nunez, L; (...); Gil-Perotin, S
Article. 10.3389/fncel.2017.00141. 2017
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Comabella, Manuel; (...); Luenemann, Jan D.
Article. 10.1007/s00415-024-12763-w. 2025
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch
Article. 10.1016/j.msard.2023.105033. 2023
Leptomeningeal gadolinium enhancement in multiple sclerosis
Gascon-Gimenez, F; (...); Casanova, V
Meeting Abstract. 2019
Leptomeningeal gadolinium enhancement lesions in multiple sclerosis are not related to different brain volume measures
Garcia, F; (...); Casanova, B
Meeting Abstract. 2018
Lipid-Specific Immunoglobulin M Bands in Cerebrospinal Fluid Are Associated with a Reduced Risk of Developing Progressive Multifocal Leukoencephalopathy during Treatment with Natalizumab
Villar LM; (...); Álvarez-Cermeño JC
Article. 10.1002/ana.24345. 2015
Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience
Rubio Alcantud, Almudena; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Long-term treatment effect over disability progression in patients with relapsing multiple sclerosis
Estruch, BC; (...); Coret, F
Meeting Abstract. 2017
Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1016/j.jns.2020.117180. 2020
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
Garcia-Foncillas, J; (...); Gomez, MVP
Review. 10.1007/s40291-021-00544-4. 2021
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis
Article. 10.1212/NXI.0000000000200069. 2023
Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors
Haines JD; (...); Lopez-Rodas G
Article. 10.1177/1352458515573094. 2015
Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura
Article. 10.1007/s10072-023-07252-3. 2023
Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus
Sepúlveda M; (...); Saiz A
Article. 10.1212/NXI.0000000000000225. 2016
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Toboso I; (...); Villar LM
Article. 10.3389/fneur.2020.579438. 2020
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
Alcala, C.; (...); Casanova, B.
Article. 10.1007/s00415-021-10926-7. 2022
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcala Vicente, Carmen; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2022.991596. 2022
Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity
Castillo, J.; (...); Casanova, B.
Meeting Abstract. 2022
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Casanova B; (...); Pérez-Miralles F
Article. 10.1016/j.msard.2022.104118. 2022
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.
Coret F; (...); Casanova B
Article. 10.1177/2055217318783347. 2018
Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
Meca-Lallana, JE; (...); Maurino, J
Article. 10.2147/PPA.S305707. 2021
Perception of stigma in patients with primary progressive multiple sclerosis.
Pérez-Miralles F; (...); Casanova-Estruch B
Article. 10.1177/2055217319852717. 2019
Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)
Lallana, Jose Meca; (...); Maurino, Jorge
Meeting Abstract. 2021
Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis
Barreiro-Gonzalez, A; (...); Casanova, B
Meeting Abstract. 2019
Potential Biomarkers Associated with Multiple Sclerosis Pathology.
Mathur, Deepali; (...); Casanova, Bonaventura
Article. 10.3390/ijms221910323. 2021
Potential Role of CHI3L1+ Astrocytes in Progression in MS.
Cubas-Núñez L; (...); Casanova B
Article. 10.1212/NXI.0000000000000972. 2021
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2024.105734. 2024
Predictive value of early brain atrophy on response in patients treated with interferon ß.
Pérez-Miralles FC; (...); Montalban X
Article. 10.1212/NXI.0000000000000132. 2015
Predictive value of isolated CSF NfL and Chi3l1 measures in clinical practice
Gil-Perotin, S; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Villacieros-alvarez, Javier; (...); Marignier, Romain
Article. 10.1212/NXI.0000000000200362. 2025
Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report
Gil-Perotin, S; (...); Casanova-Estruch, B
Article. 10.3389/fneur.2018.00340. 2018
Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
Meca-Lallana, JE; (...); Ballesteros, J
Article. 10.1371/journal.pone.0255317. 2021
Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study
Meca-Lallana, J; (...); Maurino, J
Meeting Abstract. 2020
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
Ramo-Tello, Cristina; (...); Rovira À
Article. 10.3390/jpm12010006. 2021
Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease
Alcala, C; (...); Casanova, B
Editorial Material. 10.1016/j.msard.2018.12.005. 2019
Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis: meaning and use in clinical practice
Castillo, J; (...); Casanova, B
Meeting Abstract. 2017
Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2022
Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.
Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-024-07772-6. 2024
Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)
Fernandez, Oscar; (...); Tintore, Mar
Article. 10.33588/rn.6105.2015228. 2015
Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II)
Fernandez O; (...); Grupo Post-Ectrims GP
Article. 10.33588/rn.6106.2015239. 2015
Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I)
Fernandez, O; (...); Rodriguez-Antiguedad, A
Review. 10.33588/rn.6501.2017168. 2017
Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II)
Fernandez, Oscar; (...); Rodriguez-Antiguedad, Alfredo
Review. 10.33588/rn.6502.2017169. 2017
Revision de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunion Post-ECTRIMS (I).
Fernandez O; (...); Grupo Post-Ectrims GP
Abstract of Published Item. 10.33588/rn.6105.2015228. 2015
Revision de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunion Post-ECTRIMS (II).
Fernandez O; (...); Rodriguez-Antiguedad A
Article. 10.33588/rn.6502.2017169. 2017
Risk of transition to secondary progressive multiple sclerosis and accumulation of disability in progressive multiple sclerosis are not influenced by current therapies
Alcala, C; (...); Casanova, B
Meeting Abstract. 2017
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Arrambide, Georgina; (...); Meca-Lallana, Jose E
Article. 10.1212/NXI.0000000000001024. 2021
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo, Nicolas; (...); Comabella, Manuel
Article. 10.1136/jnnp-2023-332251. 2023
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E; (...); Villar LM
Article. 10.1093/brain/awae260. 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2023
Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2024
Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis
Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).
Pérez-Miralles F; (...); Casanova B
Article. 10.1016/j.msard.2021.102860. 2021
Silent Progression or Bout Onset Progressive Multiple Sclerosis?
Gil-Perotin, S; (...); Casanova, B
Letter. 10.1002/ana.25537. 2019
Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: Real-world results and baseline characteristics of initial patients
Fernandez, O; (...); Sanchez-de la Rosa, R
Meeting Abstract. 2017
Spinal cord atrophy but not brain atrophy measures, correlates with the Multiple Sclerosis Severity Score
Carratala, S; (...); Estruch, BC
Meeting Abstract. 2018
Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.
Balzano T; (...); Felipo V
Article. 10.1186/s12974-020-01746-z. 2020
Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective
Meca-Lallana, J.; (...); Maurino, J.
Meeting Abstract. 2021
The impact of stigma in people with primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2023.1060696. 2023
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete, Lamberto; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2021.727586. 2021
Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
Alcala-Vicente, C; (...); Casanova-Estruch, B
Article. 10.33588/rn.6410.2016359. 2017
Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
Alcala, C; (...); Casanova, B
Meeting Abstract. 2018
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-019-09195-2. 2019
Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients
García-Robles AA; (...); Poveda JL
Letter. 10.1016/j.jns.2016.04.048. 2016